Matthew Gantz, Castle Creek CEO
A Jeff Aronin startup quietly yanks its IPO as the biotech market ends year on a whimper
Close to 6 months after it initially posted its S-1 in what was still a thriving biotech IPO market, Castle Creek Biosciences has now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
